期刊文献+

盐酸阿夫唑嗪缓释胶囊的制备及体外释放度研究

Preparation of alfuzosin hydrochloride sustained-release capsule and its drug release in vitro
原文传递
导出
摘要 目的:制备盐酸阿夫唑嗪缓释胶囊,观测体外释放度.方法:采用挤出-滚圆法制备载药丸芯,以Eudragit RS 30D作为主要包衣材料,制备盐酸阿夫唑嗪缓释微丸.采用紫外分光光度法建立含量测定方法,通过释放度试验评价缓释效果.结果:所制备的盐酸阿夫唑嗪缓释胶囊1,3,8h时的累积释放率分别为38.4%,70.0%,99.8%,其释药行为符合Higuchi方程(Q=0.3533t1/2+0.052,r=0.9915),缓释效果良好,3批样品与进口缓释片释放曲线基本一致.结论:研制的盐酸阿夫唑嗪缓释胶囊剂处方合理,制备工艺简单可行,释放度与进口缓释片无明显区别. AIM: To prepare alfuzosin hydrochloride sustainedrelease capsule and to test its release profile in vitro. METHODS : Extrusion-spheronisation method was introduced to prepare alfuzosin hydrochloride sustained-release pellets and Eudragit RS-30D dispersion was used as sustained-release layer. The content of alfuzosin hydrochloride was determined by UV speetrophotometry and the sustained-release profile of the capsule was evaluated by drug release test. RESULTS: The capsule demonstrated an excellent release profile and its accumulative release percentage was 38.4% ,70.0% and 99.8% at 1,3 and 8 h, respectively. The release of the drugs from pellets was in accordance with Higuchi equation ( Q = 0. 3533t^1/2 + 0. 052, r = 0. 9915 ). The release curves of three batches of samples were in general accordance with the imported alfuzosin hydroehloride sustained-release tablets. CONCLUSION: The characteristics of drug release from capsules have no difference with that of the imported tablets. The formula of alfuzosin hydroehloride sustained-release capsule is reasonable and its preparation technology is simple and feasible.
出处 《第四军医大学学报》 北大核心 2008年第21期1973-1976,共4页 Journal of the Fourth Military Medical University
关键词 盐酸阿夫唑嗪 缓释胶囊 微丸 释放度 alfuzosin hydrochloride sustained-release capsules pellets drug release
  • 相关文献

参考文献7

二级参考文献24

  • 1葛庆华,王浩,傅民,周臻,何广安,刘戈,江志强.国产硝苯地平控释片的药动学和生物等效性研究[J].高血压杂志,2005,13(5):310-312. 被引量:19
  • 2张蓉,方瑜,曹德英.格列齐特缓释微丸胶囊的制备及体外释放度考察[J].中国药业,2006,15(10):27-29. 被引量:6
  • 3NESBITT R U, MAHJOUR M, NANCY L M, et al.Effect of substrate on mass release latex coated pellets[ J ]. J Control Release, 1994, 32 ( 1 ) : 71 - 77.
  • 4MOHAMMED A. Al-Omar nimodipine: Drug metabolism and pharmacokinetic profile [ J ]. Profiles of Drug Substances, Exeipients and Related Methodology,2005(31) :371 - 375.
  • 5NIOPAS I, DAFTSIOS C A. Determination of nifedipine in human plasma by solid-phase extraction and high performance liquid chromatography: Validation and application to pharmacokinetics studies [ J ]. J Pharm Biomed Anal, 2003, 32 : 1214 - 1215.
  • 6ABOU-AUDA S H, NAJJAR A T, AL-KHAMIS I K,et al. Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies [J]. J Pharm Biomed Anal, 2000, 22 : 242 - 243.
  • 7刘海峡.尼莫地平的临床应用[J].河南实用神经疾病杂志,2000,3(6):60-61.
  • 8FABRIZIO F, CRISTINA F, ELDA D G, et al. Nimodipine selectively stimulates β-amyloid 1-42 secretion by a mechanism independent of ealeium influx blockage[J]. Neurobiology of Aging, 2006, 27(2) :218 - 227.
  • 9PATRIZIA B, RENATO U, DE ARIANNA L, et al.Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia [J].Clinical Pharmacology & Therapeutics, 2002, 72 ( 5 ) :556- 561.
  • 10ISSAC C S. Pharmaceutical pelletization technology[ M]. New York: Marcel Dekker Inc, 1989:101- 143.

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部